Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 159

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 159
---
 shares of our Common Stock at any time and from time to time during
the term of the Convertible Notes, and we may also issue additional shares of our Common Stock to Yorkville in connection with Advances
under the SEPA. The number of shares of Common Stock that are issued to Yorkville will fluctuate based on a number of factors. It is
not possible at this stage to predict the number of shares of Common Stock that will be ultimately issued pursuant to the SEPA, if not
terminated and if and when available.

Outstanding
amounts under the SEPA, if not terminated and if and when available, will make us more vulnerable to downturns in our financial condition,
and any shares of Common Stock we issue under the SEPA, if not terminated and if and when available, will further dilute our stockholders.

As
of the date of this Quarterly Statement on Form 10-Q, there are $4.0 million of Pre-Paid Advances outstanding under the SEPA, and there
may be additional amounts outstanding under the SEPA in the future. If our cash flow from operations is insufficient to meet our payments
under the SEPA, if not terminated and if and when available, or we are unable to offset amounts outstanding under the SEPA with the issuance
of shares of Common Stock, we would incur an event of default under the SEPA, in which case, all outstanding amounts would be immediately
due and payable. Any debt we incur from Yorkville or other parties could make us more vulnerable to a downturn in our operating results
or a downturn in economic conditions. If our cash flow from operations is insufficient to meet any debt service requirements or we incur
an event of default, we could be required to refinance our obligations, or dispose of assets in order to meet debt service requirements.

In
addition, any shares of Common Stock that we issue to Yorkville under the SEPA, if not terminated and if and when available, will further
dilute our current stockholders.

32

Risks
Related to the Launch of the Nugevia Brand

The
launch of the Nugevia brand exposes the Company to a number of business and operational risks that could materially and adversely impact
its business

The
launch of the Nugevia brand exposes us to a number of risks that could materially and adversely affect our business, financial condition,
and results of operations. Successfully introducing a new brand requires significant investment in marketing, product development, supply
chain management, and regulatory compliance